



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/040,128 Confirmation No. : 8763
Applicant : LIAO et al.
Filed : January 2, 2002
TC/A.U. : 1642
Examiner : Nickol, Gary B.
Docket No. : 11245/46902
Customer No. : 26646

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY

Dear Sir:

In the Office Action dated November 10, 2003, Applicants were required to elect one of the following groups of invention:


Group I: Claims 1-7 and 10-12, as specifically drawn to an antibody that binds to a site on a VE-cadherin, said site being within the about 15 N-terminal amino acids of domain 1 of a VE-cadherin including

Certificate of Mailing

I hereby certify that this **REPLY** (along with any documents referred to as attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on May 10, 2004.


Kathryn M. Lymb (Reg. No. 46, 885)

insertions, deletions or substitutions of from 1 to about 5 amino acids relative to a native VE-cadherin amino acid sequence and pharmaceutical composition thereof, classified in class 530, subclass 387.1.

- Group II: Claims 1-7 and 10-12, as specifically drawn to an antibody that binds to a peptide having an amino acid sequence of SEQ ID NO:1 and pharmaceutical composition thereof, classified in class 530, subclass 387.9.
- Group III: Claims 1-7 and 10-12, as specifically drawn to an antibody that binds to a peptide having an amino acid sequence of SEQ ID NO:2 and pharmaceutical composition thereof, classified in class 530, subclass 387.9.
- Group IV: Claims 1-7 and 10-12, as specifically drawn to an antibody that binds to a peptide having an amino acid sequence of SEQ ID NO:3 and pharmaceutical composition thereof, classified in class 530, subclass 387.9.
- Group V: Claims 8-9, as specifically drawn to ONE hybridoma which produces ONE monoclonal antibody from those listed in Groups I-IV above, classified in class 435, subclass 326.
- Group VI: Claims 13-19, drawn to methods of inhibiting angiogenesis in a mammal wherein the condition of said mammal **is solely associated with a neoplastic condition** comprising administering ONE of the pharmaceutical compositions from Groups I-IV above, classified in class 424, subclass 139.1.
- Group VII: Claims 13-14, drawn to methods of inhibiting angiogenesis in a mammal wherein the condition of said mammal **is solely associated with an ophthalmologic condition including retrolental fibroplasias, diabetic retinopathy, and neovascular glaucoma**, comprising administering ONE of the pharmaceutical compositions from Group I-IV above, classified in class 424, subclass 139.1.
- Group VIII: Claims 13-14 and 17-18, drawn to methods of inhibiting angiogenesis in a mammal wherein the condition of said mammal **is solely associated with an autoimmune disorder, collagenous vascular disease, rheumatoid arthritis, fibrotic disorders, and age-related muscular degeneration** comprising administering ONE of the pharmaceutical compositions from Groups I-IV above, classified in class 424, subclass 139.1.
- Group IX: Claims 20-21, as specifically drawn to ONE nucleic acid (and associated vector) which encodes a coding sequence for ONE of the antibodies from those listed in Groups I-IV above, classified in class 536, subclass 23.53.


Group X: Claim 22, drawn to a method of gene therapy comprising administering ONE of the nucleic acids of group IX above in a mammal to inhibit angiogenesis at a predetermined site or tumor neovascularization, classified in class 514, subclass 44.

Applicants elect, with traverse, to prosecute the invention of Group I, claims 1-7 and 10-12, as specifically drawn to an antibody that binds to a site on a VE-cadherin, and reserve the right to file a divisional application directed to the non-elected subject matter.

Applicants believe that the present application is in condition for allowance, and respectfully request that the Office pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

The Office is authorized to charge any fees that may be necessary for consideration of this paper to Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,



Kathryn M. Lumb, Reg. No. 46, 885
KENYON & KENYON
One Broadway
New York, NY 10004
(212) 908-6277 (telephone)
(212) 425-5288 (facsimile)

Dated: May 10, 2004



41
1642
[11245/46902]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : LIAO, et al.
Serial No. : 10/040,128
Filed : January 2, 2002
For : ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT
ADVERSE EFFECTS ON VASCULAR PERMEABILITY
Examiner : Gary B. Nickol
Art Unit : 1642
Confirmation No. : 8763
Customer No. : 26646

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450 on

Date: May 10, 2004

By: 
Kathryn M. Lumb (Reg. No. 46,885)

TRANSMITTAL

Sir:

Transmitted herewith for filing in the above-identified application is a Response to
Restriction Requirement.


Applicants hereby request a **five-month extension** of time for responding to the Restriction
Requirement dated November 10, 2004. The extended period for response expires on **May 10, 2004**.
Please charge the **\$2,010.00** extension fee to the deposit account of **Kenyon & Kenyon**, deposit
account number **11-0600**. The Commissioner is also authorized to charge payment of additional fees
associated with this communication or credit any overpayment to deposit account number **11-0600**.

A duplicate of this Transmittal is enclosed.

05/14/2004 SDIRETA1 00000079 110600 10040128
01 FC:1255 2010.00 DA

Respectfully submitted,
KENYON & KENYON

Dated: May 10, 2004

By: 
Kathryn M. Lumb (Reg. No. 46,885)
One Broadway
New York, New York
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)